958029-46-4

Usage

Uses

Used in Respiratory Medicine:
2-(5-bromo-2-fluoro-4-methoxyphenyl)propan-2-ol is used as a bronchodilator for the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It facilitates easier breathing by relaxing and opening the airways in the lungs.
Used in Pharmaceutical Industry:
2-(5-bromo-2-fluoro-4-methoxyphenyl)propan-2-ol is used as an active pharmaceutical ingredient in the development of inhalation therapies. It is often administered in the form of inhalers or nebulizers to provide targeted relief for respiratory symptoms.
Used in Research and Development:
2-(5-bromo-2-fluoro-4-methoxyphenyl)propan-2-ol is used as a subject of study for its potential applications in the treatment of other respiratory conditions. It has demonstrated anti-inflammatory and bronchoprotectant properties, which are being investigated for their therapeutic potential.

Upstream product

• 450-91-9 4-fluoro-2-methoxyaniline 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 914221-54-8 1-(5-bromo-2-fluoro-4-methoxyphenyl)ethan-1-one 
• 75-16-1 methylmagnesium bromide 
• 446-35-5 2,4-Difluoronitrobenzene 
• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 348-57-2 2,4-difluorobromobenzene 
• 676-58-4 methylmagnesium chloride 
• 96826-25-4 2-(2-fluoro-4-methoxyphenyl)-2-isopropanol 
• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 

Downstream Products

• 944317-92-4 1-bromo-4-fluoro-2-methoxy-5-(propan-2-yl)-benzene 
• 875548-97-3 (4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)methanol 
• 875446-29-0 [4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]boronic acid 
• 875446-37-0 anacetrapib 
• 875551-28-3 2'-(chloromethyl)-4-fluoro-5-isopropyl-2-methoxy-4'-(trifluoromethyl)biphenyl 
• 1383814-82-1 1-bromo-4-fluoro-2-methoxy-5-(1-methylvinyl)benzene 
• 1383814-83-2 4-fluoro-2-methoxy-5-(2-propenyl)phenylboronic acid 

Relevant academic research and scientific papers

Preparation method of Anacetrapib key intermediate

The invention relates to a preparation method of an Anacetrapib key intermediate 1-bromo-4-fluoro-5-isopropyl-2-methoxybenzene. The preparation method comprises the following steps: hydrolyzing an initial raw material 2,4-difluoronitrobenzene to obtain 4-fluoro-2-hydroxynitrobenzene, methylating 4-fluoro-2-hydroxynitrobenzene to obtain 4-fluoro-2-methoxynitrobenzene, carrying out nitro group reduction to form 4-fluoro-2-methoxyaniline, carrying out diazo bromination to obtain 4-fluoro-2-methoxybromobenzene, carrying out Friedel-Crafts acylation to obtain 2-fluoro-4-methoxy-5-bromoacetophenone, carrying out a condensation reaction to obtain 2-(2-fluoro-4-methoxy-5-bromophenyl)-propane-2-ol, carrying out an elimination reaction to obtain 1-bromo-4-fluoro-2-methoxy-5-(1-methylvinyl)benzene, and hydrogenating the 1-bromo-4-fluoro-2-methoxy-5-(1-methylvinyl)benzene to obtain 1-bromo-4-fluoro-5-isopropyl-2-methoxybenzene. The preparation method has the advantages of realization of low cost, good quality and high yield of the above final product, mild reaction conditions, simplicity in operation, and easiness in industrialization.

SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

Synthesis of intermediates for preparing anacetrapib and derivates thereof

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

Preparative scale synthesis of the biaryl core of anacetrapib via a ruthenium-catalyzed direct arylation reaction: Unexpected effect of solvent impurity on the arylation reaction

In this report, we disclose our findings regarding the remarkable effect of a low-level impurity found in the solvent used for a ruthenium-catalyzed direct arylation reaction. This discovery allowed for the development of a robust and high-yield arylation protocol that was demonstrated on a multikilogram scale using carboxylate as the cocatalyst. Finally, a practical, scalable, and chromatography-free synthesis of the biaryl core of Anacetrapib is described.(Figure Presented)